Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 26, 2007

Cubist Purchases Illumigen for $9M

  • Cubist Pharmaceuticals acquired Illumigen Biosciences for $9 million in cash. Illumigen shareholders stand to make up to $332.5 million based on development, regulatory, and commercialization milestones.

    Illumigen's lead compound is IB657, a protein therapeutic in preclinical development for the treatment of HCV infections. Cubist expects to file an IND application in 2008.

    Illumigen is now a wholly owned subsidiary of Cubist. During the development of IB657 for HCV infections, Cubist will pay up to $75.5 million depending on achievement of certain milestones. If IB657 is developed for the treatment of viruses other than HCV, development and regulatory milestone fees of up to $117 million could apply. Assuming that HCV or other Illumigen antiviral products are commercialized, additional milestone payments of up to $140 million as well as tiered royalties may also apply.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »